The FDA approved the oral (tablet) version of Novo Nordisk's Wegova, making it the first GLP-1 tablet approved for the treatment of obesity in the U.S.[1][2] The manufacturer said the tablet is taken once daily and is an alternative to the injectable form of Wegova.Novo Nordisk claims that the oral form achieves the same weight loss as the injectable version of Wegova.[1][2] Novo Nordisk1][2][3][4][5] The approval of the tablet form is based on the results of phase 3 clinical trials, which demonstrated significant weight loss and tolerability comparable to the injectable form (the trials included a 64-week evaluation and compared a daily dose of 25 mg to placebo).3][5] The manufacturer expects to launch sales of the pill in the U.S. in the near term following approval.[2][3][3] The approval may expand access to obesity treatment by offering patients an oral option instead of injections.[3][3][3][4] The approval may expand access to obesity treatment by offering patients an oral option instead of injections.